Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Sponsor
Aditya Bagrodia
Study ID
NCT07733908
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Posluma PET — DIAGNOSTIC_TEST
    Posluma® (flotufolastat F 18) is an FDA-approved diagnostic PET imaging agent used to detect prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. It helps pinpoint the location of cancer when metastasis is suspected or when recurrence occurs due to elevated PSA levels.

Study Details

To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.

Key Dates

First listed
Jul 29, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030

Study Design

Enrollment
22 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Posluma PET
    Participants will undergo Posluma PSMA PET scans at two time points: preoperatively to evaluate the extent of disease prior to focal therapy and postoperatively for monitoring treatment success and detecting potential recurrence. The Posluma PET imaging will be conducted on a PET/CT scanner with optimized protocols for PCa lesion detection. PET scan data will be analyzed in comparison with MRI and biopsy results. All imaging will be performed at UCSD, ensuring consistent imaging quality and scanner calibration across all patients.

Primary Outcome Measure

Diagnostic performance of Posluma PSMA PET scan for prostate cancer after focal therapy [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies